Advertisement
U.S. markets closed
Advertisement

Alimera Sciences, Inc. (ALIM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
3.5400+0.1300 (+3.81%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close3.4100
Open3.3300
Bid1.4100 x 4000
Ask3.5500 x 1400
Day's Range3.3300 - 3.6100
52 Week Range1.3000 - 3.9000
Volume74,386
Avg. Volume38,033
Market Cap185.555M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-1.7100
Earnings DateOct 26, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALIM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alimera Sciences, Inc.
    Daily – Vickers Top Insider Picks for 01/05/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Alimera Appoints Maggie A. Pax to Its Board of Directors

    Maggie A. Pax Maggie A. Pax Appointed to Board of Directors of Alimera Sciences ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. “Maggie’

  • GlobeNewswire

    Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology

    ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg taken from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN for patients with di

  • Insider Monkey

    Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript

    Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript October 26, 2023 Alimera Sciences, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.41. Operator: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Third Quarter 2022 [2023] (sic) Financial Results and Corporate Update Conference Call. [Operator […]